bioAffinity Technologies, Inc. (BIAF) Scorecard
- 2026-Q2: Total return Lose; Revenue growth Lose; EPS growth Lose.
- 2026-Q1: Total return Win; Revenue growth Lose; EPS growth Lose.
- 2025-Q4: Total return Lose; Revenue growth Lose; EPS growth Win.
- 2025-Q3: Total return Lose; Revenue growth Lose; EPS growth Win.
17/120
All 120 Win/Lose results shown below
Every strict quarterly win earns 1 point. A loss, tie, or unavailable scoring value earns 0.
Trailing 1 year (4 quarters): 3 wins, 9 lossesLast fetched: 4 Sept 2026
Complete point ledger
Each cell identifies the missing side explicitly.
| Quarter | Total return | Revenue growth | EPS growth |
|---|---|---|---|
| 2026-Q20/3 |
LoseBIAF / S&P -78.80% / 15.20% |
LoseBIAF / S&P -23.17% / 15.00% |
LoseBIAF / S&P -65.22% / 50.40% |
| 2026-Q11/3 |
WinBIAF / S&P 224.58% / -4.33% |
LoseBIAF / S&P -35.75% / 11.30% |
LoseBIAF / S&P -27.19% / 27.70% |
| 2025-Q41/3 |
LoseBIAF / S&P -60.14% / 2.65% |
LoseBIAF / S&P -34.18% / 9.00% |
WinBIAF / S&P 36.58% / 13.40% |
| 2025-Q31/3 |
LoseBIAF / S&P -65.62% / 8.12% |
LoseBIAF / S&P -27.66% / 4.61% |
WinBIAF / S&P 280.51% / 13.45% |
| 2025-Q22/3 |
LoseBIAF / S&P 10.38% / 10.94% |
WinBIAF / S&P 4.99% / 4.83% |
WinBIAF / S&P 2206.59% / 10.63% |
| 2025-Q12/3 |
LoseBIAF / S&P -71.43% / -4.27% |
WinBIAF / S&P 78.40% / 4.98% |
WinBIAF / S&P 1651.09% / 10.57% |
| 2024-Q42/3 |
LoseBIAF / S&P -56.25% / 2.41% |
WinBIAF / S&P 269.68% / 5.25% |
WinBIAF / S&P 1178.89% / 6.15% |
| 2024-Q32/3 |
LoseBIAF / S&P -3.70% / 5.89% |
WinBIAF / S&P 2813.87% / 5.89% |
WinBIAF / S&P 1207.14% / 6.11% |
| 2024-Q22/3 |
WinBIAF / S&P 6.93% / 4.28% |
WinBIAF / S&P 30187.24% / 5.38% |
LoseBIAF / S&P -31.58% / 5.12% |
| 2024-Q12/3 |
WinBIAF / S&P 37.32% / 10.56% |
WinBIAF / S&P 86182.88% / 5.71% |
LoseBIAF / S&P -20.69% / 5.59% |
| 2023-Q41/3 |
WinBIAF / S&P 26.37% / 11.69% |
LoseBIAF / S&P BIAF unavailable / 6.81% |
LoseBIAF / S&P BIAF unavailable / 7.78% |
| 2023-Q30/3 |
LoseBIAF / S&P -36.39% / -3.27% |
LoseBIAF / S&P BIAF unavailable / 7.52% |
LoseBIAF / S&P BIAF unavailable / -5.03% |
| 2023-Q20/3 |
LoseBIAF / S&P -3.17% / 8.74% |
LoseBIAF / S&P BIAF unavailable / 9.50% |
LoseBIAF / S&P BIAF unavailable / -8.57% |
| 2023-Q11/3 |
WinBIAF / S&P 18.13% / 7.50% |
LoseBIAF / S&P BIAF unavailable / 10.77% |
LoseBIAF / S&P BIAF unavailable / -15.69% |
| 2022-Q40/3 |
LoseBIAF / S&P -45.02% / 7.56% |
LoseBIAF / S&P BIAF unavailable / 11.88% |
LoseBIAF / S&P BIAF unavailable / -17.99% |
| 2022-Q30/3 |
LoseBIAF / S&P BIAF unavailable / -4.88% |
LoseBIAF / S&P BIAF unavailable / 13.47% |
LoseBIAF / S&P BIAF unavailable / -1.41% |
| 2022-Q20/3 |
LoseBIAF / S&P BIAF unavailable / -16.10% |
LoseBIAF / S&P BIAF unavailable / 13.71% |
LoseBIAF / S&P BIAF unavailable / 11.04% |
| 2022-Q10/3 |
LoseBIAF / S&P BIAF unavailable / -4.60% |
LoseBIAF / S&P BIAF unavailable / 15.97% |
LoseBIAF / S&P BIAF unavailable / 42.23% |
| 2021-Q40/3 |
LoseBIAF / S&P BIAF unavailable / 11.03% |
LoseBIAF / S&P BIAF unavailable / 15.00% |
LoseBIAF / S&P BIAF unavailable / 96.40% |
| 2021-Q30/3 |
LoseBIAF / S&P BIAF unavailable / 0.58% |
LoseBIAF / S&P BIAF unavailable / 10.77% |
LoseBIAF / S&P BIAF unavailable / 69.42% |
| 2021-Q20/3 |
LoseBIAF / S&P BIAF unavailable / 8.55% |
LoseBIAF / S&P BIAF unavailable / 6.58% |
LoseBIAF / S&P BIAF unavailable / 51.81% |
| 2021-Q10/3 |
LoseBIAF / S&P BIAF unavailable / 6.17% |
LoseBIAF / S&P BIAF unavailable / -1.06% |
LoseBIAF / S&P BIAF unavailable / 7.39% |
| 2020-Q40/3 |
LoseBIAF / S&P BIAF unavailable / 12.15% |
LoseBIAF / S&P BIAF unavailable / -3.72% |
LoseBIAF / S&P BIAF unavailable / -33.42% |
| 2020-Q30/3 |
LoseBIAF / S&P BIAF unavailable / 8.93% |
LoseBIAF / S&P BIAF unavailable / -2.04% |
LoseBIAF / S&P BIAF unavailable / -27.10% |
| 2020-Q20/3 |
LoseBIAF / S&P BIAF unavailable / 20.54% |
LoseBIAF / S&P BIAF unavailable / -0.46% |
LoseBIAF / S&P BIAF unavailable / -27.11% |
| 2020-Q10/3 |
LoseBIAF / S&P BIAF unavailable / -19.60% |
LoseBIAF / S&P BIAF unavailable / 3.47% |
LoseBIAF / S&P BIAF unavailable / -14.75% |
| 2019-Q40/3 |
LoseBIAF / S&P BIAF unavailable / 9.07% |
LoseBIAF / S&P BIAF unavailable / 5.36% |
LoseBIAF / S&P BIAF unavailable / 2.99% |
| 2019-Q30/3 |
LoseBIAF / S&P BIAF unavailable / 1.70% |
LoseBIAF / S&P BIAF unavailable / 5.02% |
LoseBIAF / S&P BIAF unavailable / 0.21% |
| 2019-Q20/3 |
LoseBIAF / S&P BIAF unavailable / 4.30% |
LoseBIAF / S&P BIAF unavailable / 6.64% |
LoseBIAF / S&P BIAF unavailable / 8.65% |
| 2019-Q10/3 |
LoseBIAF / S&P BIAF unavailable / 13.65% |
LoseBIAF / S&P BIAF unavailable / 8.12% |
LoseBIAF / S&P BIAF unavailable / 14.29% |
| 2018-Q40/3 |
LoseBIAF / S&P BIAF unavailable / -13.52% |
LoseBIAF / S&P BIAF unavailable / 9.05% |
LoseBIAF / S&P BIAF unavailable / 18.23% |
| 2018-Q30/3 |
LoseBIAF / S&P BIAF unavailable / 7.71% |
LoseBIAF / S&P BIAF unavailable / 10.21% |
LoseBIAF / S&P BIAF unavailable / 19.06% |
| 2018-Q20/3 |
LoseBIAF / S&P BIAF unavailable / 3.43% |
LoseBIAF / S&P BIAF unavailable / 9.03% |
LoseBIAF / S&P BIAF unavailable / 14.46% |
| 2018-Q10/3 |
LoseBIAF / S&P BIAF unavailable / -0.76% |
LoseBIAF / S&P BIAF unavailable / 7.68% |
LoseBIAF / S&P BIAF unavailable / 12.46% |
| 2017-Q40/3 |
LoseBIAF / S&P BIAF unavailable / 6.64% |
LoseBIAF / S&P BIAF unavailable / 7.03% |
LoseBIAF / S&P BIAF unavailable / 13.82% |
| 2017-Q30/3 |
LoseBIAF / S&P BIAF unavailable / 4.48% |
LoseBIAF / S&P BIAF unavailable / 5.68% |
LoseBIAF / S&P BIAF unavailable / 17.57% |
| 2017-Q20/3 |
LoseBIAF / S&P BIAF unavailable / 3.09% |
LoseBIAF / S&P BIAF unavailable / 4.83% |
LoseBIAF / S&P BIAF unavailable / 17.74% |
| 2017-Q10/3 |
LoseBIAF / S&P BIAF unavailable / 6.07% |
LoseBIAF / S&P BIAF unavailable / 3.67% |
LoseBIAF / S&P BIAF unavailable / 13.32% |
| 2016-Q40/3 |
LoseBIAF / S&P BIAF unavailable / 3.82% |
LoseBIAF / S&P BIAF unavailable / 2.09% |
LoseBIAF / S&P BIAF unavailable / 7.05% |
| 2016-Q30/3 |
LoseBIAF / S&P BIAF unavailable / 3.85% |
LoseBIAF / S&P BIAF unavailable / 0.20% |
LoseBIAF / S&P BIAF unavailable / -3.15% |
Dividend-reinvested, split-adjusted total return
1Y · 2025-08-29 to 2026-08-27
| Metric | BIAF total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -30.30% | 20.78% |
| Annualized return | -30.30% | 20.78% |
5Y · 2022-09-01 to 2026-08-27
| Metric | BIAF total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -97.97% | 83.14% |
| Annualized return | -54.12% | 12.86% |
10Y · 2022-09-01 to 2026-08-27
| Metric | BIAF total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -97.97% | 319.30% |
| Annualized return | -32.27% | 15.41% |
Calculation rules
- window
- Latest 40 completed benchmark quarters; unavailable issuer evidence remains visible and scores 0.
- return Basis
- Issuer adjusted close reinvests distributions and normalizes splits; the S&P 500 Total Return Index is the direct benchmark.
- point Rule
- Strict same-quarter win = 1. Loss, tie or unavailable evidence = 0. No partial or subjective points.
- frequency
- Quarter endpoints only.
- fundamentals
- Trailing-four-quarter issuer revenue and EPS growth use the issuer's normalized government-filed facts.
- non Scoring
Snapshot captured 2026-09-04.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| OneMedNet Corp (ONMD) | $0.042B | ||
| iSpecimen Inc. (ISPC) | United States | $0.003B | |
| MAXCYTE, INC. (MXCT) | United States | $0.124B | -3.68 |
| FOXO TECHNOLOGIES INC. (FOXO) | United States | $0.000B | -277.71 |
| NRC HEALTH (NRC) | United States | $0.450B | 42.50 |
| OmniAb, Inc. (OABI) | United States | $0.698B | -8.05 |
| Absci Corp (ABSI) | United States | $1.775B | -14.92 |
| CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL) | United States | $14.060B | -43.97 |
| Medpace Holdings, Inc. (MEDP) | United States | $17.316B | 30.09 |
| INCYTE CORP (INCY) | United States | $24.855B | 13.14 |